Abstract: A method and system extends the functionality of the Open Mobile Alliance (OMA) Device Management (DM) standard to manage vendor specific configuration parameters and settings. An OMA DM structure is provided as an extension to the tree structure of the OMA DM standard. The OMA DM extension allows selected vendor specific parameters and settings to be managed under the OMA DM protocol.

Abstract: Embodiments provide a security infrastructure that may be configured to run on top of an existing operating system to control what resources can be accessed by an applications and what APIs an application can call. Security decisions are made by taking into account both the current thread's identity and the current thread's call chain context to enable minimal privilege by default. The current thread context is captured and a copy of it is created to be used to perform security checks asynchronously. Every thread in the system has an associated identity. To obtain access to a particular resource, all the callers on the current thread are analyzed to make sure that each caller and thread has access to that resource. Only when each caller and thread has access to that resource is the caller given access to that resource.

Abstract: The invention provides methods for detecting the presence or absence of invasive trophoblast cells. In addition, the invention provides methods for distinguishing quiescent trophoblast diseases from invasive trophoblast diseases and methods for monitoring progression of quiescent trophoblast diseases. The invention provides methods for detecting the presence or absence of germ cell tumors.

Abstract: The present invention relates to compositions and methods for treating cancer, especially epithelial and eutopic cancers using inhibitors of H-HCG or ?-H-HCG, as well as vaccines for use in oncostasis or reducing the likelihood of recurrence of cancer after remission. In addition, the present invention provides a method for reducing the likelihood that a woman will become pregnant or that an unwanted pregnancy may be terminated.

Abstract: The present invention relates to a novel method of determining the existence of a normal pregnancy which has a high likelihood of culminating in a term pregnancy, by measuring hyperglycosylated hCG in a pregnant woman and comparing the concentration of measured hyperglycosylated hCG with a predetermined value. A measurement of hyperglycosylated hCG above the predetermined value, for example, about 13 ng/ml, is evidence of a high likelihood of a normal pregnancy. A measurement below the predetermined value is evidence of an abnormal pregnancy (ectopic pregnancy or miscarriage). Further analysis of the patient in the event that the measurement falls below the predetermined value is made by intravaginal or abdominal ultrasound to determine whether or not the pregnancy is ectopic or will likely result in a spontaneous abortion (miscarriage).

Abstract: Embodiments provide a security infrastructure that may be configured to run on top of an existing operating system to control what resources can be accessed by an applications and what APIs an application can call. Security decisions are made by taking into account both the current thread's identity and the current thread's call chain context to enable minimal privilege by default. The current thread context is captured and a copy of it is created to be used to perform security checks asynchronously. Every thread in the system has an associated identity. To obtain access to a particular resource, all the callers on the current thread are analyzed to make sure that each caller and thread has access to that resource. Only when each caller and thread has access to that resource is the caller given access to that resource.

Abstract: A method for predicting pregnancy outcome includes measuring blood levels of hCG-hg and progesterone in a pregnant woman, determining a rate of change of progesterone levels from the blood measurements, determining at least a qualitative direction of change of hCG-hg levels from the blood measurements, comparing the determined rate of change of progesterone levels with a pre-established reference value, and determining at least a qualitative likelihood of a term pregnancy and a failed pregnancy for the woman from the qualitative direction of change of hCG-hg levels and the determined rate of change of progesterone levels relative to the pre-established reference value. The rate of change of progesterone is determined by formula as a number of days for progesterone to double.

Abstract: The invention provides prenatal screening methods for Down's syndrome. Specifically, the methods of the invention comprise determining the amount of hyperglycosylated human chorionic gonadotropin (hCG) charge isoforms in a biological sample from a pregnant woman and comparing the amount of highly acidic and less acidic isoforms with those found in a sample taken from a pregnant woman carrying a normal fetus. The methods of the invention can be employed during any stage of pregnancy.

Abstract: The present invention relates to compositions and methods for reducing the likelihood that a woman will become pregnant or that an unwanted pregnancy may be terminated by administering an inhibitor of H-hCG or ?-H-hCG to said a woman at risk to become pregnant. Methods of enhancing the likelihood that a fertilized egg will successfully implant in a woman's endometrium and successfully be carried to term are additional aspects of the present invention.

Abstract: The present invention relates to methods for analyzing concentrations of hyperglycosylated hCG (H-hCG) and hCG equally in blood, serum or urine samples, preferably urine samples, from female patients to determine with an unexpectedly high measure of accuracy whether or not the patient is pregnant and to appropriately monitor hCG levels during the course of pregnancy. In preferred aspects of the present invention, the method utilizes an assay system which can be used in the home or at a point of care facility in a convenient manner with serum or urine samples, in a highly accurate predictive manner. It can also be used in a serum professional laboratory quantitative test.

Abstract: A method for predicting pregnancy outcome includes measuring blood levels of hCG-hg and progesterone in a pregnant woman, determining a rate of change of progesterone levels from the blood measurements, determining at least a qualitative direction of change of hCG-hg levels from the blood measurements, comparing the determined rate of change of progesterone levels with a pre-established reference value, and determining at least a qualitative likelihood of a term pregnancy and a failed pregnancy for the woman from the qualitative direction of change of hCG-hg levels and the determined rate of change of progesterone levels relative to the pre-established reference value. The rate of change of progesterone is determined by formula as a number of days for progesterone to double.

Abstract: The present invention relates to compositions and methods for treating cancer, especially epithelial and eutopic cancers using inhibitors of H-HCG or ?-H-HCG, as well as vaccines for use in oncostasis or reducing the likelihood of recurrence of cancer after remission. In addition, the present invention provides a method for reducing the likelihood that a woman will become pregnant or that an unwanted pregnancy may be terminated.

Abstract: Methods for detecting pregnancy in a woman comprise screening a biological sample of the woman for pregnancy markers. The methods of the invention include chemiluminescent assays for the pregnancy markers. The methods of the invention also comprise utilizing at least two capture antibodies that specifically bind different epitopes of the pregnancy marker in one assay. The methods of the invention permit detection of pregnancy within about 7 days after ovulation or implantation.

Abstract: The invention provides prenatal screening methods for Down's syndrome. Specifically, the methods of the invention comprise determining the amount of hyperglycosylated human chorionic gonadotropin (hCG) charge isoforms in a biological sample from a pregnant woman and comparing the amount of highly acidic and less acidic isoforms with those found in a sample taken from a pregnant woman carrying a normal fetus. The methods of the invention can be employed during any stage of pregnancy.

Abstract: The invention provides methods for detecting the presence or absence of invasive trophoblast cells. In addition, the invention provides methods for distinguishing quiescent trophoblast diseases from invasive trophoblast diseases and methods for monitoring progression of quiescent trophoblast diseases. The invention provides methods for detecting the presence or absence of germ cell tumors.

Abstract: A prenatal screening method for Down's syndrome involves assaying for hyperglycosylated gonadotropin in biological test samples such as urine, plasma or serum obtained from pregnant women. Hyperglycosylated gonadotropin comprises a variant population of chorionic gonadotropin, chorionic gonadotropin-free &bgr;-subunit, &bgr;-core fragment, and/or free &agr;-subunit exhibiting differences in the carbohydrate content from what is observed in samples obtained from pregnant women carrying normal fetuses. Qualitative or quantitative observation of differences in the carbohydrate content of the hyperglycosylated gonadotropin population from corresponding control samples containing a normal gonadotropin population, or direct observation of the variant species seen in Down's syndrome, indicates that the woman's fetus has Down's syndrome. Typical screens involve carbohydrate analyses, immunoassays, or combinations of these methods.

Abstract: A substantially pure human chorionic gonadotropin beta subunit nicking enzyme (GBNE) has been purified from human blood serum. GBNE nicks the beta-subunit of human chorioinic gonadotropin at either Arg-44 or Gly-47, is an arginine specific metalloprotease, has an apparent molecular weight of between 150,000 and 430,000 daltons, and is partially inhibited by phenanthroline or leupeptin.

Abstract: A method for detecting the progression or regression of a gynecologic cancer in a female by:(a) taking a first measurement of the amount of human chorionic gonadotropin beta-subunit core fragment in a bodily non-blood fluid sample from a female known to be suffering from a gynecologic cancer,(b) subsequent to step (a), taking one or more further measurements of human chorionic gonadotropin beta-subunit core fragment from a bodily non-blood fluid sample from the female,(c) comparing the first measurement to said one or more further measurements to ascertain if the human chorionic gonadotropin beta-subunit core fragment is increasing or decreasing, as an indication that the cancer is respectively progressing or regressing.